ArticleThe New England journal of medicine2019
Treatment of Progressive Multifocal Leukoencephalopathy with Pembrolizumab.
Article in The New England journal of medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed.
- Adoptive T-cell therapy for virus-associated diseases.Clinical microbiology reviews · 2025Review
- Ten Years ofNeurology(R) neuroimmunology & neuroinflammation · 2025Article
- Combined treatment with allogeneic Epstein-Barr- and human polyomavirus 1 specific T-cells in progressive multifocal leukoencephalopathy and EBV infection: a case report.Therapeutic advances in neurological disorders · 2024Article
- Long-term outcome of progressive multifocal leukoencephalopathy with recombinant interleukin-2 treatment and an associated increase in the number of HPyV-2-specific T-cells: a case report.Therapeutic advances in hematology · 2023Article
- Survival and prognostic factors of progressive multifocal leukoencephalopathy in people living with HIV in modern ART era.Frontiers in cellular and infection microbiology · 2023Article
- Promise and Challenges of Checkpoint Inhibitor Therapy for Progressive Multifocal Leukoencephalopathy in HIV.Current HIV/AIDS reports · 2022Review
- [Immune checkpoint inhibitors in the treatment of progressive multifocal leukoencephalopathy].Der Nervenarzt · 2022Article
- Innovative therapeutic concepts of progressive multifocal leukoencephalopathy.Journal of neurology · 2022Review
- The neuroradiology of progressive multifocal leukoencephalopathy: a clinical trial perspective.Brain : a journal of neurology · 2022Review
- It was 40 Years Ago Today: AIDS and the Brain.Neurocritical care · 2022Article
- Sequential treatment of progressive multifocal leukoencephalopathy with intravenous immunoglobulins and pembrolizumab.Journal of neurovirology · 2022Article
- Pembrolizumab treatment of inflammatory progressive multifocal leukoencephalopathy: a report of two cases.Journal of neurovirology · 2022Article
- Article
- Leveraging Systems Immunology to Optimize Diagnosis and Treatment of Inborn Errors of Immunity.Frontiers in systems biology · 2022Article
- Advances in Treatment of Progressive Multifocal Leukoencephalopathy.Annals of neurology · 2021Review
- Article
- Hematopoietic Stem Cell Transplantation Cures Chronic Aichi Virus Infection in a Patient with X-linked Agammaglobulinemia.Journal of clinical immunology · 2021Article
- Combined Treatment With Pembrolizumab and Allogenic BK Virus-Specific T Cells in Progressive Multifocal Leukoencephalopathy: A Case Report.Neurology(R) neuroimmunology & neuroinflammation · 2021Article
- Single-Dose Pembrolizumab Treatment for Progressive Multifocal Leukoencephalopathy.Neurology(R) neuroimmunology & neuroinflammation · 2021Article
- Immune Reconstitution Syndrome After Nivolumab for Progressive Multifocal Leukoencephalopathy.Neurology. Clinical practice · 2021Article
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
8 authors.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
30969507What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.